

ARTÍCULO DE MAYOR FACTOR DE IMPACTO JULIO 2015

Zhu, AX; Park, JO; Ryoo, BY; Yen, CJ; Poon, R; Pastorelli, D; Blanc, JF; Chung, HC; Baron, AD; Pfiffer, TEF; Okusaka, T; Kubackova, K; Trojan, J; Sastre, J; Chau, I; Chang, SC; Abada, PB; Yang, L; Schwartz, JD; Kudo, M. *Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial*

Lancet Oncology: 2015 JULIO; 16(7):859-70. doi: 10.1016/S1470-2045(15)00050-9.

FACTOR DE IMPACTO: 24,725

Enlace: <http://www.sciencedirect.com/science/article/pii/S1470204515000509>

THE LANCET Oncology

Volume 16, Issue 7, July 2015, Pages 859–870



Articles

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

Dr Andrew X Zhu, MD^a, Joon Oh Park, MD^b, Baek-Yeol Ryoo, MD^c, Chia-Jui Yen, MD^d, Ronnie Poon, MD^e, Davide Pastorelli, MD^f, Jean-Frederic Blanc, MD^g, Hyun Cheol Chung, MD^h, Ari D Baron, MDⁱ, Tulio Eduardo Flesch Pfiffer, MD^j, Takuji Okusaka, MD^k, Katerina Kubackova, MD^l, Jorg Trojan, MD^m, Javier Sastre, PhDⁿ, Ian Chau, MD^o, Shao-Chun Chang, MD^p, Paolo B Abada, MD^q, Ling Yang, MS^r, Jonathan D Schwartz, MD^s, Masatoshi Kudo, MD^t, for the REACH Trial Investigators[†]

[Show more](#)

Choose an option to locate/access this article: